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A
range of hemostats have been re-
ported that decrease the time re-
quired to establish hemostasis by
dehydrating the injury site,1,2 concentrating
clotting factors,2,3 delivering clotting agents
(such as thrombin and ﬁbrinogen)1,2,4 or for-
ming a physical barrier against bleeding,5 to
the injured site to promote clotting. However,
most of these hemostats are suitable for
external wounds,6,7 where hemostatic agents
and external pressure can be applied simul-
taneously. Recently, thrombin and ﬁbrino-
gen-based injectable solutions have been
developed, but these injectable solution-
based hemostats pose the risk of introducing
strong coagulation activators into the circula-
tory system.8,9 Therefore, there is a need for
new hemostatic biomaterials that are inject-
able into a wound, mechanically stable, and
induce rapid and local hemostasis.
One approach to developing hemostatic
agents for traumatic injuries is to engineer
injectable biomaterials that can be intro-
duced into a wound site, forming a physio-
logically stable artiﬁcial matrix and pro-
moting the natural clotting cascade. Speci-
ﬁcally, the biomaterial should ﬂow with
minimal applied pressure during injection,
providing a method of application that
avoids additional patient trauma. However,
once in the wound, the material should
solidify to prevent biomaterial loss to un-
aﬀected areas. Shear-thinning hydrogels
can satisfy these requirements and have
been developed from a wide variety of
material platforms.10,11
Multiple approaches have been devel-
oped to incorporate functional materials
into hemostats to enhance their therapeu-
tic properties. These include commercial
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ABSTRACT Internal hemorrhaging is a leading cause of death after
traumatic injury on the battleﬁeld. Although several surgical approaches such
as the use of ﬁbrin glue and tissue adhesive have been commercialized to
achieve hemostasis, these approaches are diﬃcult to employ on the battleﬁeld
and cannot be used for incompressible wounds. Here, we present shear-
thinning nanocomposite hydrogels composed of synthetic silicate nanoplatelets
and gelatin as injectable hemostatic agents. These materials are demonstrated
to decrease in vitro blood clotting times by 77%, and to form stable clot-gel systems. In vivo tests indicated that the nanocomposites are biocompatible and
capable of promoting hemostasis in an otherwise lethal liver laceration. The combination of injectability, rapid mechanical recovery, physiological stability, and
the ability to promote coagulation result in a hemostat for treating incompressible wounds in out-of-hospital, emergency conditions.
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products such as QuikClot that incorporate kaolin, a
crystalline mineral that functions as an absorbent and
coagulation activator.12 Floseal uses gelatin and throm-
bin to promote clotting in an injectable form.8 An emer-
ging approach to integrate functionality into hydrogel
networks focuses on incorporating nanoparticles.1317
Nanomaterials have been shown to interact with blood
to promote clotting via mechanisms such as platelet
activation, dehydration of the plasma, delivery of
coagulating factors, formation of physical barriers, or
the activation of clotting factors.1,1822
Highly charged nanoparticles, such as synthetic sil-
icate nanoplatelets, have been shown to induce blood
coagulation by concentrating clotting factors.4 Syn-
thetic silicates are charged disks, 2030 nm in dia-
meter and∼1 nm in thickness.23 Due to the anisotropic
distribution of their surface charge, positive along the
edge and negative on the top and bottom surfaces, the
nanoplatelets can form self-assembled structures
which can dynamically form and break, creating shear
thinning gels when in aqueous media.24 Recently, syn-
thetic silicate nanoplatelets have been used as osteo-
genic agents,23 drug delivery agents,25 tissue engi-
neered scaﬀolds,2629 solid hemostat products,4,30,31
additives in cosmetic creams,32,33 and rheological
modiﬁers.34 Synthetic silicates such as Laponite are
shown to degrade into nontoxic components (Naþ,
Mg2þ, Si(OH)4, Li
þ) in physiological conditions.35 More-
over, these silicates are found to be cytocompatible
with human stem cells and animal cells as reported in
previous literature.23,26,28
Natural and synthetic polymers have been shown
to interact with synthetic silicates through phys-
ical interactions, forming physically cross-linked
networks.26,28,29,36,37 Earlier studies on silicategelatin
interactions show that polyampholytic gelatin, con-
taining positive and negative regions, strongly inter-
acts with the oppositely charged areas of the synthetic
silicate nanoplatelets.38 Gelatin is denatured collagen,
and mimics components of the native extracellular
matrix (ECM) in structure and chemical composition.39
Gelatin's hygroscopic property also allows for absorp-
tion of body ﬂuids and is proposed for a range of tissue
engineering applications.
RESULTS/DISCUSSION
Characterization of Nanocomposites. Physical mixtures
of gelatin and silicate nanoplatelets were used to
formulate the nanocomposite hydrogels for this study.
Briefly, the silicate nanoplatelets were exfoliated in
ultrapure (Milli-Q) water using a vortexer to enhance
the surface area available for interaction with gelatin.
Next, a gelatin stock, heated to liquefy the solution, was
vigorously mixed with the exfoliated silicate at room
temperature (Figure 1a). Vigorous agitation was nec-
essary to prevent clumping of the nanoplatelets dur-
ing gelation; however, the nanoplatelets are stably
dispersed after the gel has set.24 Nanocomposite hydro-
gelswere fabricatedwith solid concentrations of 3, 6, and
9wt%andgelatin/nanoplatelet ratios from0:1 to 1:0 and
labeled as xNCy (“x” represents the total solid weight
percent and “y” is percent of the total solid weight
percent that is nanoplatelet) (Supporting Information,
Table S1). Initially, the gelatin solution was a viscous
liquid (at 37 C), but once silicate nanoplatelets were
mixed with gelatin, the solution gelled within a minute.
When mixed with gelatin, silicate nanoplatelets
improved the thermal stability of the hydrogel. Ther-
mal stability of the nanocomposite formulations was
determined by oscillatory shear rheology over a tem-
perature range from 15 to 45 C, mimicking common
environmental and physiological temperatures that
the nanocomposite may be exposed during sample
preparation and in vivo application. 9NC0 had a
gelsol transition temperature of 32 C (Supporting
Information, Figure S1), consistent with the literature
and too low for application as a hemostat.40 However,
the addition of silicate nanoplatelets to gelatin im-
proved the thermal stability, increasing the sol
gel transition to above 45 C for solids concentrations
of 6 wt % or greater. In contrast, 3 wt % solids nano-
composites were not solid within the experimentally
observed temperature range. For treatment of hemor-
rhage, thermal stability is necessary once the nano-
composite is injected so that it can remain at the
wound site without ﬂowing into adjacent areas.
Similarly, physiological stability was observed for all
9 wt % nanocomposites, 6NC50, 6NC75, and 6NC100
(Supporting Information, Figure S2). All gelatin sam-
ples, quickly dissolved in PBS at 37 C while the afore-
mentioned samples had no observed weight loss over
24 h. For this reason, only nanocomposite hydrogels
withmore than 6wt% solidswere characterized further.
Zeta potential measurements suggest that electro-
static interactions between nanoplatelets and gelatin
contributed to the observed increase in the thermal
stability (Figure 1b). Solutions of silicate nanoplatelets
possessed a zeta potential of39 mV, whereas gelatin
solutions had a zeta potential of 10 mV. Because the
two components had opposite charges, electrostatic
interactions between silicate and gelatin were ex-
pected. This was also supported by earlier ﬁndings
which showed that strong interactions betweenmont-
morillonite (another type of silicate clay) and gelatin
can function to increase the solgel transition tem-
perature of the composite.41
Scattering measurements of nanocomposite hy-
drogels suggest the presence of disk shaped particles,
indicating that clay particles remain exfoliated in the
nanocomposite. Small angle X-ray scattering (SAXS)
intensity curves of the nanocomposites showed power
law decay with an exponent of 2 at high q, greater
than 0.03 Å1, characteristic of disk-shaped scatterers.
The scattering intensity from 9NC75 can be ﬁt with a
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thin disk model42 with a radius of 9.5 ( 2.7 nm, in
agreement with the reported size of the silicate nano-
platelets (Figure 1c).23 This suggests that scattering was
produced from individual nanoplatelets dispersed with-
in the gelatin in this formulation and not aggregates of
nanoplatelets (Supporting Information, Figure S3).
Silicate addition to gelatin modulated the rheolo-
gical response of the nanocomposite, resulting in a
shear yielding behavior observed at 37 C. Preliminary
investigations using a 22-gauge needle indicated that
all silicate-containing nanocomposite hydrogels could
be injected and form self-supporting structures, sug-
gesting the presence of a yield stress and recovery
potential (Figure 1a). Linear oscillatory shear rheology
showed that the crossover frequency was below 0.001
Hz for 9NC75 and 9NC100, maintaining solid-like (G0 >
G00) properties over the tested frequency range
(Supporting Information, Figure S4). Oscillatory strain
into the nonlinear regime (Supporting Information,
Figure S4) illustrated yielding behavior, an important
parameter for designing hydrogels for minimally in-
vasive therapies. In oscillatory shear rate sweeps, the
yield stress was deﬁned as a 5% departure of the stress
from the initial linearity on a stressstrain plot. Tests
were performed at 37 C, where gelatin readily ﬂows
and lacks a yield stress (Figure 1d; Supporting Informa-
tion, Figure S4). An increase in the silicate concentra-
tions from 0% (9NC0) to 100% (9NC100) increased the
yield stress from 2 to 89 Pa. A yield stress was observed
in 9NC100 but not in 9NC0, suggesting that the yield
stress behavior was derived from the presence of the
dispersed nanoplatelets in the nanocomposite, consis-
tent with the known shear thinning capability of
nanoplatelets.40 Because increasing concentration of
gelatin reduces the yield stress, it eases delivery of the
nanocomposite by injection.
Recovery of the elastic gel strength in less than
10 seconds was observed in nanocomposites for
Figure 1. Structure, injectability, and self-healing characteristics of nanocomposite hydrogels. (a) Schematic showing the
preparation of the nanocomposite gels. The TEM image shows the size of the silicate nanoparticle (scale bar 50 nm). Images
showing injection of nanocomposite hydrogel through a surgical needle (22 gauge) and recovery to form freestanding
structures. (b) Zeta potential measurements demonstrate electrostatic interactions between negatively charged silicate and
positively charged gelatin; 95% CI are shown for each point. (c) Small-angle X-ray scattering (SAXS) indicates that
nanoplatelets are well dispersed and follow the model curve for scattering from dispersed thin disks. (d) Yield stress of
gels as a function of nanoplatelet loading and solids fraction. (e) Recovery of the nanocomposites was observed by subjecting
the hydrogel to alternating high and low strain conditions (100% strain and 1% strain) while monitoring the moduli of the
composite. For all the nanocomposite hydrogels, more than 95% recovery was observed.
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nanoplatelet loadings greater than 50% (9NC50,
9NC75, and 9NC100). Such rapid self-healing after
the removal of stress can prevent material ﬂow after
application to a wound site. Other physically cross-
linked hydrogels are capable of recovering their
prestrained moduli in seconds (i.e. telechelic protein
gels)43 to tens of minutes (i.e. peptide amphiphile gels)5
after the cessation of shear. Therefore, the rapid recov-
ery time of these gels provides a signiﬁcant advantage
by reducing the risk being washed away because they
have relatively long self-healing times after the defor-
mation of physically cross-linked networks.5 Figure 1e
shows four cycles of high (100%) to low (1%) oscillatory
strain amplitudes and the resulting nanocomposite
moduli. At 100% oscillatory strain, all apparent moduli
are below 100 Pa by the end of 5minutes of oscillation,
illustrating rapid network disruption. After four cycles
of high and low oscillatory strain, the 9NC50 modulus
during 100% strain oscillations was 80% lower than the
initial modulus during high strain. At higher silicate
loading (9NC75 and 9NC100), the moduli were 33%
and 29% lower compared to the initial values during
high strain. In contrast, the moduli for the high nano-
particlematerials increased under quiescent conditions.
While 9NC50 showed a 13.5% decrease after four strain
cycles, 9NC75 and 9NC100 showed 9.3% and 13.3%
increases in modulus, respectively. Extended monitor-
ing (Supporting Information, Figure S5) indicated
that after 30 seconds the quiescent moduli reached
asymptotic values, indicating completion of the heal-
ing process. These results indicate rapid recovery of
the storage modulus after repeated application of
high oscillatory strain amplitudes, suggesting rapid
recovery of the physically cross-linked networks.
In Vitro Performance of Nanocomposite in the Presence of
Whole Blood. The incorporation of silicate nanoplatelets
into gelatin led to a decrease in the observed clotting
time in vitro. The hemostatic ability of nanocomposite
hydrogels was evaluated by monitoring the clotting
time of whole blood in contact with the nanocompo-
site surfaces in 96-well plates. Under normal condi-
tions, human blood initiates coagulation in 56
min.4,44 Similar clotting times (5.2( 0.5 min) for whole
blood were observed in control wells containing
neither gelatin nor nanocomposite (Figure 2a,b). A
slight color change was observed in 9NC0 by 5 min.
This was attributed to the tamponade ability of
gelatin.45 Gelatin is hygroscopic and could absorb
Figure 2. Eﬀect of nanoplatelets on the clotting whole blood. (a) Clot formation as a function of time and nanocomposite
composition. (b) Quantiative clot times for 6% and 9% nanocomposites. (One-way Anova followed by Tukey's post-hoc
analysiswas performed; *p<0.01; ***p<0.001). (c) Clotting kinetics of bloodwhen in contactwith gelatin andnanocomposite
monitored using shear rheology. (d) Comparison of clotting times for silicate-gelatin nanocomposite (NC) and commercial
products.
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the fluid components of whole blood but could not
stimulate clot formation within 5 min. The addition of
nanoplatelets to gelatin reduced blood clotting time in
a dose-dependent manner. Figure 2a,b demonstrates
the decreased clotting time for higher nanoplatelet
concentrations. 9NC25, 9NC50, and 9NC75 reduced
the clotting time by 32%, 54%, and 77%, respectively,
when compared to the control (blood in uncoated
wells). The representative images of wells at select time
points, shown in Figure 2a, clearly highlight the pre-
sence of a clot earlier in nanocomposites with higher
nanoplatelet loadings. This was attributed to the
strong negative charge of the synthetic silicate nano-
platelet that can facilitate concentration of clotting
factors near the nanocomposite surface. Prior studies
have shown a decrease in clotting time due to the
addition of negatively charged particles to polymer
hydrogels.4,12 Preliminary in vitro studies indicate that
the nanocomposites induced minimal cytotoxic effect
or inflammatory response (Supporting Information,
Figure S6), with gelatin-containing nanocomposites
having higher cell viability and lower inflammatory
response than NC100 gels, supporting the potential
application of these materials as biocompatible hemo-
static gels.
Decreased clotting times of blood in contact with
nanocomposites were also observed through rheolo-
gical measurements. Small amplitude oscillatory time
sweeps of blood in contact with gelatin or gelatin
silicate nanocomposites were performed to evaluate
clotting kinetics (Figure 2c. Gelatin was chosen as
a control, having minimal impact on clotting time
in vitro. 9NC75 was selected for its combination of
decreased clotting time, comparable to 9NC100 which
was the best performer in vitro, and its decreased
inﬂammatory response when compared to 9NC100,
insigniﬁcant from the inﬂammatory response of 9NC0
(Supporting Information, Figure S6). Clotting induced
an increase in the elastic modulus of the gelatin-clot
system from 101 to 104 Pa (Figure 2c). Whole blood in
contactwith gelatin begins cloting in 57min, which is
consistent with our earlier clotting data and the
literature.46 When gelatin was replacedwith a silicate
gelatin nanocomposite, the clotting transition oc-
curred even prior to the initiation of measurements,
reﬂecting a large reduction in the clotting time. Com-
paring the decrease in clotting time observed with
nanocomposites to other reported hemostatic pro-
ducts, the improvement exceeds many solid hemo-
stats and was similar to recorded values for thrombin-
based hemostats (Figure 2d).4,6,46,47 A comparison of
the nanocomposite and the commercial hemostat
QuikClot clot mass per contact area as a function of
time showed similar trends in clot formation
(Supporting Information, Figure S7).
Blood clot strength was preserved in blood-nano-
composite systems. Clot strength, characterized by the
peak shear stress attained in a linearly increasing strain
experiment, is a parameter important for establishing
hemostasis. More rigid clots aremore likely to embolize
while more pliable clots are ineﬀective. Stressstrain
curves of each system were compared to a natural clot
under the same testing conditions. The results indicate
that the clot could sustain a peak shear stress of 2.4 (
0.3 kPa, while the gelatin-clot system had a peak shear
stress of 0.5 kPa (Supporting Information, Figure S8).
The liquid-like properties of gelatin (G00 > G0) at 37 C
compromise the mechanical stability of the system.
Nanocomposites tested under the same conditions
reached a maximum shear stress of 1.0 ( 0.09 kPa. In
the presence of nanocomposite, the shear stress of a
nanocomposite-clot was 1.9 ( 0.6 kPa, which is com-
parable to the peak stress borne by the clot.
It was hypothesized that the surface charge of the
nanocomposite facilitated platelet aggregation or ac-
tivation of clotting factors that ultimately enhanced
the hemostatic activity. To conﬁrm this, a channel was
generated within the nanocomposite hydrogels and
subsequently ﬁlled with blood. It was observed that
platelets aggregated near the nanocomposite surface
(Supporting Information, Figure S9), which was not
observed in control experiments on gelatin or plastic
surfaces. This indicates that nanocomposite surfaces
might be eﬀective in attracting blood components.
Observations in the presence of platelet rich plasma
(PRP) and platelet poor plasma (PPP) (Supporting
Information, Figure S9) indicated that components in
both plasma types were colocalized with silicates,
forming aggregates around the silicates. This colocali-
zation and protein adsorption to the nanocomposite
surfaces could be driven by electrostatic or hydropho-
bic interactions, which have been shown to determine
protein adsorption to biomaterial surfaces.48,49 The ﬁrst
row of images in Supporting Information, Figure S9
shows a uniform ﬂuorescence from a silicate nano-
platelet solution. The second row (whole blood) shows
blood cells with a minimal ﬂuorescent signature. The
mixture of labeled 9NC100 and PPP showed colocali-
zation of the plasma components with the silicate
nanoplatelets (third row). The same was observed for
the nanoplatelets and PRP (fourth row). The uniform
ﬂuorescence of the nanoplatelets is disrupted by the
presence of blood components, suggesting a change
in the interactions between nanoplatelets. The coloca-
lization of silicates and blood components is thought
to originate from plasma proteins and blood cells
interacting with the charged surfaces of silicate nano-
platelets, increasing blood component concentrations
surrounding the nanocomposite. Earlier studies have
shown that charge interactions can initiate the coagu-
lation cascade, such as the interactions of GPIb-V
receptors (negative) with platelets and von Willebrand
factor (positive) with collagen.20,50,51 The attractive
properties of the silicates could serve to accelerate
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hemostasis,with similar proteinnanocomposite inter-
actions observed in other hemostats.47
In Vivo Hemostatic Potential of Nanocomposite in Liver
Bleeding Model. In vivo biocompatibility of nanocompo-
site hydrogels was investigated by dorsal subcutane-
ous injection in rats via 1 cm incisions. 9NC75 (200 μL)
or QuikClot samples (200μL) were injected or implanted,
respectively, in subcutaneous pockets (n = 16) as shown
in Figure 3a. All animals survived the follow-up period
of 28 days without any signs of physical impairment or
systemic inflammation, and exhibited regular somatic
growth. After 3 days, both implant materials (9NC75
Figure 3. In vivo evaluationof nanocomposite hydrogels as hemostats. (a) Subcutaneous injection and explantation of 9NC75
in rats. After 3 days, nanocomposite could be easily detected in the subcutaneous pockets, but the volumewas already lower
than at implantation. (b) H&E staining conﬁrmed degradation of 9NC75 within 28 days, while the QuikClot particles were still
present. Moreover, 9NC75 induced less chronic inﬂammation thanQuikClot, indicated by severemononuclear cell inﬁltration
around QuikClot at day 28 (asterisks). Furthermore, the QuikClot samples were encapsulated by dense ﬁbrous connective
tissue (arrows). The potential of the nanocomposite to stop otherwise lethal bleeding was investigated using liver bleeding
experiments in rats. (c) 9NC75 signiﬁcantly improved the postinterventional survival (logrank (Mantel-Cox) test). (d) 9NC75
was eﬀective in preventing blood loss as compared to untreated hemorrhage (***p < 0.001). (e) The small amount of 9NC75
(200 μL) was suﬃcient to stop bleeding and the superﬁcial part of the 9NC75was easily removedwithout causing rebleeding.
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and QuikClot) could be easily detected in the subcu-
taneous pockets. At day 28, the QuikClot particles
appeared macroscopically unchanged and 9NC75 was
integrated in the surrounding tissue. Hematoxylin &
Eosin (H&E) staining confirmed these observations
indicating that 9NC75 was predominantly degraded
within 28 days after injection, while QuikClot did not
undergo degradation (Figure 3b).52 Both implants in-
duced an acute locally restricted inflammatory reaction
in the host, including cellular infiltration. This process
turned into chronic inflammation of the surrounding
tissue, whereas the inflammatory response against
QuikClot was substantially stronger when compared
to 9NC75, resulting in a higher density and larger area
of predominantly mononuclear cellular infiltrates.
Moreover, in the QuikClot group, dense fibrous tissue
formation was detected around the implants at day 28,
indicating fibrous capsule formation (Figure 3b).
To investigate the potential of the nanocomposite
to stop otherwise lethal bleeding, a standardized liver
bleeding model was applied (Supporting Information,
Figure S10). In the liver bleeding experiments (n =
12 rats), median laparotomy was performed, and the
central liver lobe was exposed. After draping of the
surrounding situs with ﬁlter paper for blood collection,
a circular liver laceration (1 cm diameter) with standar-
dized shape and size was created. Immediately after
the injury, 9NC75 or QuikClot was applied on the site of
lesion. The principal lethality of this bleeding model
was assessed in control animals (n = 5) without appli-
cation of a hemostat. Both 9NC75 (n = 5) and QuikClot
(n = 2) were eﬀective in stopping relevant hemorrhage
within seconds and prevented hypovolemic condi-
tions. A log rank analysis of the early postinterventional
survival data revealed signiﬁcant improvement by the
nanocomposite (logrank (Mantel-Cox) test: p = 0.007
versus control; hazard ratio 11.5 with 95%CI 1.9368.9)
(Figure 3c). The total blood loss after 5 and 10 minutes
was signiﬁcantly decreased by the application of
9NC75 (p < 0.001 versus control) (Figure 3d). The small
amount of applied nanocomposite (200 μL) was more
than suﬃcient, since the superﬁcial parts of the nano-
composite were not soaked with blood, and thorough
removal of this excess material did not cause rebleed-
ing (Figure 3e). All hemostat-treated liver bleeding
animals survived the complete follow-up period of
28dayswithout secondary hemorrhage. At explantation,
no remnants of the nanocompositewere observed and
the liver presented an intact surface, while QuikClot
was still present, accompanied by soft tissue adhesion
to the site of lesion. These results show that the
nanocomposite gel oﬀers a strong hemostatic poten-
tial for in vivo applications and is suitable to stop lethal
bleeding.
CONCLUSION
In conclusion, nanocomposite hydrogels containing
synthetic silicate disks and gelatin form injectable
biomaterials that can promote in vitro and in vivo
coagulation. The addition of silicate nanoplatelets to
gelatin signiﬁcantly improved the physiological stabi-
lity, injectability, hemostatic performance, and nano-
composite-clot strength. Future studies into the long-
term eﬀects of the nanocomposite in vivo will be
required in any translational applications. In addition,
the ability of the nanocomposite to be used as a
delivery vehicle for additional clotting or regenerative
signaling molecules will be an area for continued
investigation. Due to these unique features, the newly
developed silicate based gelatin nanocomposite can
be used as an injectable hemostat to treat incompres-
sible wounds.
METHODS
Materials. Synthetic silicate nanoplatelets (Laponite XLG)
were purchased from Southern Clay Products, Inc. (Louisville,
KY). Type-A porcine skin gelatin was obtained from Sigma-
Aldrich (Milwaukee, WI). Zeta potentials of gelatin, silicate
nanoplatelet, and mixtures of silicate and gelatin were deter-
mined in ultrapure water (Milli-Q) and phosphate buffered
saline (PBS), pH 7.4 (Invitrogen) using a 633 nm laser in a
Malvern ZEN3600 (Malvern Instruments, U.K.). Silicate nanopla-
telets were dissolved with vigorous agitation (vortexing) while
gelatin was dissolved with stirring at 40 C. Transmission
election microscopy (TEM) images of the silicate nanoplatelets
were obtained using a JEOL JEM-1400 TEM (JEM1400) installed
with a cool beam illumination system (resolution: 0.2 nm line,
0.38 nm point) and 11 megapixel Advanced Microscopy Tech-
niques cooled charged coupled device camera at 80 kV. The
sample was prepared by dispersing silicate nanoplatelets in
water/ethanol solutions, placing a drop on the TEM grid, and
allowing the grid to dry under vacuum.
Nanocomposite Formulation. Stock solutions of 18% (w/w) ge-
latin and 9, 6, or 3% (w/w) nanoplatelets were prepared in water
(Supporting Information Table S1). Milli-Q water was heated to
40 C to dissolve gelatin. Water (4 C) was used for nanoplatelet
stock solutions to retard the gelation and allow for full dissolu-
tion of nanoplatelet particles prior to gelling. The nanoplatelet
gels were allowed to sit at room temperature to fully hydrate
until a clear gel was formed. The nanocomposite compositions
were made by vortexing the gelatin stock, nanoplatelet stock,
and Milli-Q water at 3000 rpm for 5 min to achieve the correct
solid concentration and nanoplatelet loading. Nanocomposites
were again heated and vortexed. The nanocomposites were
then stored at 4 C.
Nanocomposite Degradation. Nanocomposite samples were
placed in 2.0 mL Eppendorf tubes and weighed. Each sample
was centrifuged in a swinging bucket rotor centrifuge to obtain
a flat interface. Each sample was soaked in phosphate buffered
saline (pH 7.4; Invitrogen), stored at 37 C. At set times, the PBS
was removed, and the nanocomposite reweighed. The change
in weight was recorded up to 24 h after initial soaking. PBS was
replaced after each weighing.
Rheological Analysis. An Anton Paar MCR 301 rheometer was
used for mechanical testing. A 25 mm diameter parallel plate
geometry with a gap height of 500 μm was used for tempera-
ture sweeps and mineral oil was placed around the circumfer-
ence of the plate to prevent evaporation of water from the
nanocomposite for all tests. Nanocomposites were equilibrated
A
RTIC
LE
GAHARWAR ET AL. VOL. 8 ’ NO. 10 ’ 9833–9842 ’ 2014
www.acsnano.org
9840
for 10 min prior to testing, followed by a 2 min steady shear at
10 s1. This was enough time to allow the viscosity to reach a
minimum, shear thinning the hydrogel and removing the
mechanical history. Ten seconds of equilibrium time was suffi-
cient for the viscosity to return to a higher plateau value, after
which point testing was initiated. Frequency and shear rate
sweeps were performed at 20 and 37 C, sweeping frequencies
from 0.001 to 100 Hz at 1% strain and shear rates from 0.001 to
100 s1 with 10 points/decade. Frequency sweeps were per-
formedwith a cone geometry (25mmdiameter, 1 angle, 50 μm
truncation gap). Stress-controlled temperature sweeps were
performed from 15 to 45 C at 10 Pa stress and 1 Hz. All other
tests were performed at 37 C. Oscillatory stress sweeps were
performed from 0.01 to 100 Pa at 1 Hz. Strain sweeps were
performed from 0.01 to 1000% at 1 Hz. Recovery testing was
conducted at 1 Hz by applying 100% strain, a value outside of
the linear viscoelastic range, followed by 1% strain for 5 min to
monitor gel recovery. Interfacial strength was also measured by
applying a linearly increasing strain to a system of nanocompo-
site and coagulated blood. Shear stress was measured until
1800% strain. The maximum stress attained was used as a
measure of the strength of the clot system.
Clotting Time Assay. A volume of 630 μL citrated blood was
pipetted into a 1.5 mL Eppendorf tube. A total of 70 μL of 0.1 M
calcium chloride (CaCl2) was then added, followed by vortexing
for 10 s. Then, 50 μL was deposited into sequential wells on a 96
well plate. At selected time points, each well was washed with
9 g/L saline solution to halt clotting. The liquid was immediately
aspirated and washes repeated until the solution was clear,
indicating removal of all soluble blood components. When
testing the nanocomposites, the nanocomposites were injected
via syringe into the base of the well plates, ensuring the entire
bottom surface was coated with gel. After a trial was complete,
the final clotting time was marked in the well that formed a
uniform clot, with no change in clot size in subsequent wells.
Quantification and Imaging of Interfacial Interactions. Anticoagu-
lated whole blood was centrifuged for 2 min to separate red
blood cell-rich (RBC-rich) and RBC-poor phases in a mini cen-
trifuge (6000 rpm). A liquid solution of fluorescently labeled
nanoplatelet was mixed with the RBC-rich and -poor phases.
Repeated spin downs and washings were performed to remove
unbound nanoplatelets. Dilute solutions of RBC-rich/nanoplate-
let and RBC-poor/nanoplatelet were mixed and deposited onto
glass slides for imaging with a fluorescence microscope.
SAXS Method. Small Angle X-ray Scattering (SAXS) was per-
formed at the NSLS at Brookhaven National Laboratory at
beamline X27C. Samples were placed in a 1 mm thick washer
and sealed between Kapton tape. Samples were equilibrated at
37 and 20 C for 20 min prior to collection of data. Scattering
patternswere collected for 30 s per sample. Radial integration of
the two-dimensional scattering pattern was performed to yield
a one-dimensional scattering curve, which was corrected for
empty cell and dark field scattering. Thin disk form factor model
fitting was performed in MatLab using a nonlinear fit algorithm
to fit the radius and a Gaussian distribution for polydispersity of
the nanocomposite.
Thrombus Weight. Nanocomposite and powdered QuikClot
samples were weighed into 2 mL Eppendorf tubes. Nanocom-
posites were centrifuged to standardize the surface area ex-
posed. Citrated blood was reactivated by 10% (v/v) 0.1 M CaCl2.
A total of 100 μL of solution (10 μL CaCl2 and 90 μLwhole blood)
was added to each Eppendorf tube. At each measured time
point, clotting was stopped by addition of 200 μL sodium citrate
solution (0.109 M). Any liquid was removed from the Eppendorf
tube, leaving only clotted blood. The Eppendorf tubes were
reweighed to determine the mass of clot produced in the tube.
Clot mass was normalized to the area exposed to the nano-
composite. The same area was used for the commercial hemo-
stat sample.
Cell Studies. Mouse monocyte/macrophage RAW 264.7 cells
were procured from the ATCC. RAW 264.7 cells were grown in
Dulbecco'sModified Eagle'sMedium (DMEM) supplementedwith
10% FBS and 1% penicillin/streptomycin at 37 C in 5% CO2.
Lipopolysaccharide (LPS) was obtained from InvivoGen. RAW
264.7 macrophages were suspended in different formulations
of gelatin and silicate at a concentration of 3 106 cells/mL and
plated at a density of 2000 cells/well and grown for 24 hours. As
controls, RAW cells were untreated or treatedwith 100 ng/mL of
LPS. An ELISA assay (SA Biosciences) was performed according
to the manufacturer's protocol on the supernatants of different
groups to quantify the secreted cytokines IL-6 and TNF-R by the
RAW cells. In another study, the cell viability of RAW cells in the
presence of gelatin and silicate for 24 hours was measured with
Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation MTS
Assay (Promega) according to manufacturer's protocol using a
plate reader at 490 nm absorbance. To eliminate possible
absorbance from silicate or gelatin components, the absor-
bance values with gelatin, silicate and nanocomposite hydro-
gels, without cells, were measured. These absorbance values
were subtracted from the corresponding absorbance values for
gelatin, silicate and nanocomposite hydrogels, with cells. This
resulted in reading the absorbance values of only viable cells.
Each tested hydrogel was measured in three separate wells.
In Vivo Experiments. MaleWistar rats (n = 20; 200250 g) were
obtained from Charles River (Wilmington, MA), housed in the
local animal care facility (PRB, Cambridge, MA) and fed ad
libitum. Anesthesia and analgesia were achieved by isoflurane
inhalation (2.02.5%) and subcutaneous carprofen administra-
tion (5 mg/kg/d). All experiments were conducted according to
the NIH “Guide for the Care and Use of Laboratory Animals”, and
approved by the local animal care committee (HMA Standing
Committee on Animals; protocol number 05055).
For subcutaneous implantation procedures (n = 8 rats),
dorsal skin incisions (1 cm in length) were conducted, a small
subcutaneous pocket was generated by blunt preparation, and
nanocomposite gels (n = 8; 200 μL) were injected or QuikClot
samples (n = 8; 200 μL) were implanted, respectively. The
wounds were anatomically closed, and the animals were
allowed to recover from anesthesia. After 3 and 28 days, the
animals were euthanized by CO2 inhalation, and the implants as
well as adjacent tissuewere explanted and further processed for
histological analyses.
In the liver bleeding experiments (n = 12 rats), median
laparotomy was performed and the central liver lobe was ex-
posed. After draping of the surrounding situswith ﬁlter paper for
blood collection, a standardized circular liver laceration was
created by gluing a plastic disc (d = 10 mm) to the surface and
superﬁcially excising this area with a blade. Immediately after the
injury, nanocomposite gel (n=5; 200μL) orQuikClot (n=2; 200μL)
was applied on the site of lesion. Five minutes after the bleed-
ing had been stopped, the abdomen was anatomically closed,
and the animals were allowed to recover from anesthesia. After
28 days, the animalswere euthanized byCO2 inhalation, and the
site of injury was inspected. To examine the principal lethality of
the liver bleeding model, control rats (n = 5) underwent liver
injury without subsequent application of a hemostat. In all liver
bleeding experiments, the amount of bleeding was determined
by weighing the blood-soaked ﬁlter papers after removal.
Histological analyses were conducted as previously
published.52 In brief, paraformaldehyde-ﬁxed cryosections
(6 μm) of all explants were stained with hematoxylin/eosin
and microscopically analyzed.
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